The stable overexpression of CPEB4 did not obviously affect cell proliferation or survival (Figure 2B), however, it markedly increased the survival rate of both two ovarian cancer cell lines when treated with paclitaxel (Figure 2C). Here, CPEB4 is linked to ovarian cancer.